2. GPCR/G Protein Immunology/Inflammation
  3. CXCR
  4. ACT-777991

ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11.

For research use only. We do not sell to patients.

ACT-777991 Chemical Structure

ACT-777991 Chemical Structure

CAS No. : 1967811-46-6

Size Price Stock Quantity
5 mg USD 1360 In-stock
10 mg USD 2042 In-stock
25 mg USD 3880 In-stock
50 mg USD 5820 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

ACT-777991 Related Antibodies

Top Publications Citing Use of Products

View All CXCR Isoform Specific Products:

View All Isoforms
CXCR CXCR1 CXCR2 CXCR3 CXCR4 CXCR7 CXCR6

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11[1].

IC50 & Target[1]

CXCR3

 

In Vitro

ACT-777991 inhibits hEGR with an IC50 value of 26 μM in CHO cells[1].
ACT-777991 (1 μM; 45 min) is stable in microsomes and hepatocytes across humans, rats, and dogs[1].
ACT-777991 (0.01-1 μM; ) inhibits the migration of both human and mouse-activated T cells toward CXCL11 with IC50s range of 3.2-64 nM and 4.9-21 nM, respectively[1].
ACT-777991 (1 nM, 5 nM, 20 nM, and 50 nM) inhibits CXCR3-mediated chemotaxis of human and mouse T cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ACT-777991 Related Antibodies
In Vivo

ACT-777991 (0.5 mg/kg, 1 mg/kg; i.v.; single dose) has low in vivo plasma clearance in male Wistar rats (14/156) or Beagle dogs (5/15)[1].
ACT-777991 (0.006-2 mg/g food; po; started 3 days before and 72 h post LPS challenge) dose-dependently inhibits chemotaxis of CXCR3+ T cells in vivo in mouse model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: LPS challenge model in mice[1]
Dosage: 0.006, 0.02, 0.06, 0.2, 0.6, and 2 mg per g of food
Administration: PO; started 3 days before LPS challenge and continued up to the end of the study (72 h post LPS challenge)
Result: Reduced the number of BAL CD8+ T cells in a dose-dependent manner.
Clinical Trial
Molecular Weight

550.48

Formula

C20H20F6N8O2S
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OCC[C@@H](N(C(CN1C=NC(C)=N1)=O)CC2)CN2C(SC(C(F)(F)F)=N3)=C3C4=CN=C(C(F)(F)F)N=C4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (181.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8166 mL 9.0830 mL 18.1660 mL
5 mM 0.3633 mL 1.8166 mL 3.6332 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.54 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.54 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.86%

COA (254 KB) HNMR (143 KB) RP-HPLC (232 KB) LCMS (203 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.8166 mL 9.0830 mL 18.1660 mL 45.4149 mL
5 mM 0.3633 mL 1.8166 mL 3.6332 mL 9.0830 mL
10 mM 0.1817 mL 0.9083 mL 1.8166 mL 4.5415 mL
15 mM 0.1211 mL 0.6055 mL 1.2111 mL 3.0277 mL
20 mM 0.0908 mL 0.4541 mL 0.9083 mL 2.2707 mL
25 mM 0.0727 mL 0.3633 mL 0.7266 mL 1.8166 mL
30 mM 0.0606 mL 0.3028 mL 0.6055 mL 1.5138 mL
40 mM 0.0454 mL 0.2271 mL 0.4541 mL 1.1354 mL
50 mM 0.0363 mL 0.1817 mL 0.3633 mL 0.9083 mL
60 mM 0.0303 mL 0.1514 mL 0.3028 mL 0.7569 mL
80 mM 0.0227 mL 0.1135 mL 0.2271 mL 0.5677 mL
100 mM 0.0182 mL 0.0908 mL 0.1817 mL 0.4541 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ACT-777991 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ACT-7779911967811-46-6ACT777991ACT 777991CXCRCXC chemokine receptorsC-X-C motif chemokine receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ACT-777991
Cat. No.:
HY-149055
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.